Amgen to Pick Up Peptide Drug Firm KAI Pharmaceuticals for $315M Genetic Engineering News It is being studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. Through this acquisition, Amgen will acquire worldwide rights excluding Japan to KAI-4169. Amgen to Acquire Privately Held KAI Pharmaceuticals Amgen to Pay $315M for Privately-Held KAI Pharma Amgen To Buy KAI Pharma For $315 Million In Cash |
